Sjogren's Syndrome Clinical Trial Pipeline Shows Potential with Active Contributions from 10+ Key Companies | DelveInsight

DelveInsight's "Sjogren's syndrome Pipeline Insight 2025" report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Sjogren's syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Sjogren's Syndrome Research. Learn more about our innovative pipeline today! @ Sjogren's Syndrome Pipeline Outlook- https://www.delveinsight.com/sample-request/sjogrens-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Sjogren's Syndrome Pipeline Report
• On February 04, 2026- Novartis Pharmaceuticals conducted a study is to measure the long-term safety and tolerability of ianalumab in participants with Sjogrens syndrome who have previously completed treatment from one of two NEPTUNUS 1 year core studies (CVAY736A2301 [NCT05350072] or CVAY736A2302 [NCT05349214]).
• On February 04, 2026- Bristol-Myers Squibb initiated a phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome (POETYK SjS-1)
• DelveInsight's Sjogren's Syndrome pipeline report depicts a robust space with 10+ active players working to develop 12+ pipeline therapies for Sjogren's Syndrome treatment.
• The leading Sjogren's Syndrome Companies such as Johnson & Johnson, Novartis, Amgen, Artiva Biotherapeutics, Immunovant Sciences, Astellas Pharma Inc, RemeGen Co., Ltd., Rise Therapeutics LLC, Bristol-Myers Squibb, Argenx, Otsuka Pharmaceutical, Resolve Therapeutics, AbbVie and others.
• Promising Sjogren's Syndrome Pipeline Therapies such as Baricitinib, Hydroxychloroquine, HZN-1116, Nipocalimab, RSLV-132, Lanraplenib, Filgotinib, Tirabrutinib, RO5459072 and others.

Stay informed about the cutting-edge advancements in Sjogren's Syndrome treatments. Download for updates and be a part of the revolution in Immunological and Autoimmune Disorders Care @ Sjogren's Syndrome Clinical Trials Assessment- https://www.delveinsight.com/sample-request/sjogrens-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Sjogren's Syndrome Emerging Drugs Profile
• VAY736: Novartis
VAY736 (Ianalumab) is a novel, defucosylated, human IgG1/κ monoclonal antibody that targets the human B cell-activating factor (BAFF) of the TNF family. The BAFF receptor is predominantly expressed on B cells and is critically involved in B cell maturation, activation, and survival. VAY736 targets the BAFF receptor and competitively inhibits BAFF binding to BAFF-R, thereby blocking BAFF-R-mediated signaling in B cells. It is also engineered to effectively eliminate B cells from circulation in vivo by antibody-dependent cellular cytotoxicity (ADCC). The ADCC activity of ianalumab is greatly enhanced by eliminating fucose residues from the carbohydrate moiety attached to the Fc part of the antibody. The molecule is being developed by Novartis in partnership with MorphoSys as an antibody-based therapy. The drug is currently in Phase III clinical studies for the treatment of Sjögren's Syndrome.

• Nipocalimab: Johnson & Johnson
IMAAVY is a monoclonal antibody, designed to bind with high affinity to block FcRn and reduce levels of circulating immunoglobulin G (IgG) antibodies that underlie generalized myasthenia gravis (gMG) without additional detectable effects on other adaptive and innate immune functions. The investigational monoclonal antibody is designed to bind with high affinity to block FcRn and reduce levels of circulating immunoglobulin G (IgG) auto and alloantibodies potentially without additional detectable effects on other adaptive and innate immune functions. The drugs has also been granted Breakthrough Therapy designation for for Sjögren's disease by the US FDA. Currently, the drug is in Phase III stage of its development for the treatment of Sjogren's syndrome.

• Allogeneic NK Cells: Artiva Biotherapeutics
AlloNK is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the ADCC effect of mAbs to drive B-cell depletion. AlloNK, as a non-genetically modified, non-targeted NK cell, is designed to utilize a mAb or NK engager for targeting, and therefore can be used in different combinations against different therapeutic targets. Currently, the drug is in Phase II stage of its development for the treatment of Sjogren's syndrome.

• ASP5502: Astellas Pharma Inc
ASP5502 is an investigational small-molecule drug developed by Astellas Pharma, designed to inhibit the STING (Stimulator of Interferon Genes) pathway, which plays a crucial role in innate immune responses and is implicated in autoimmune conditions like primary Sjögren's syndrome. By targeting this pathway, ASP5502 aims to modulate the immune system's activity, potentially alleviating the chronic inflammation and glandular dysfunction characteristic of the disease. Notably, ASP5502 was identified through Astellas's innovative use of artificial intelligence in drug discovery, highlighting a modern approach to developing treatments for complex autoimmune disorders. Currently, the drug is in Phase I stage of its development for the treatment of Sjogren's syndrome.

The Sjogren's Syndrome Pipeline Report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Sjogren's Syndrome with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Sjogren's Syndrome Treatment.
• Sjogren's Syndrome Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Sjogren's Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Sjogren's Syndrome market.

Learn more about Sjogren's Syndrome Drugs opportunities in our groundbreaking Sjogren's Syndrome research and development projects @ Sjogren's Syndrome Unmet Needs- https://www.delveinsight.com/sample-request/sjogrens-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Sjogren's Syndrome Companies
Johnson & Johnson, Novartis, Amgen, Artiva Biotherapeutics, Immunovant Sciences, Astellas Pharma Inc, RemeGen Co., Ltd., Rise Therapeutics LLC, Bristol-Myers Squibb, Argenx, Otsuka Pharmaceutical, Resolve Therapeutics, AbbVie and others.

Sjogren's syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Sjogren's Syndrome Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Discover the latest advancements in Sjogren's Syndrome treatment by visiting our website. Stay informed about how we're transforming the future of Immunological and Autoimmune Disorders @ Sjogren's Syndrome Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/sjogrens-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Sjogren's Syndrome Pipeline Report
• Coverage- Global
• Sjogren's Syndrome Companies- Johnson & Johnson, Novartis, Amgen, Artiva Biotherapeutics, Immunovant Sciences, Astellas Pharma Inc, RemeGen Co., Ltd., Rise Therapeutics LLC, Bristol-Myers Squibb, Argenx, Otsuka Pharmaceutical, Resolve Therapeutics, AbbVie and others.
• Sjogren's Syndrome Pipeline Therapies- Baricitinib, Hydroxychloroquine, HZN-1116, Nipocalimab, RSLV-132, Lanraplenib, Filgotinib, Tirabrutinib, RO5459072 and others.
• Sjogren's Syndrome Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Sjogren's Syndrome Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Sjogren's Syndrome Pipeline on our website @ Sjogren's Syndrome Emerging Drugs and Companies- https://www.delveinsight.com/sample-request/sjogrens-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of contents
1. Introduction
2. Executive Summary
3. Sjogren's syndrome: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Sjogren's syndrome- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. VAY736: Novartis
9. Drug profiles in the detailed report.....
10. Mid Stage Products (Phase II)
11. Product Name: Company Name
12. Drug profiles in the detailed report.....
13. Early Stage Products (Phase I)
14. Product Name: Company Name
15. Drug profiles in the detailed report.....
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report.....
19. Inactive Products
20. Sjogren's syndrome Key Companies
21. Sjogren's syndrome Key Products
22. Sjogren's syndrome- Unmet Needs
23. Sjogren's syndrome- Market Drivers and Barriers
24. Sjogren's syndrome- Future Perspectives and Conclusion
25. Sjogren's syndrome Analyst Views
26. Sjogren's syndrome Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.